Novo Nordisk A/S (NVO)
What changed in recent filings
- Institutions — 2 new · 1 added · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Novo Nordisk A/S recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- FY25Report filed Feb 4, 2026Revenue +6.4% YoY · EPS $23.03Release time unknown: Feb 3 close → Feb 5 close, the stock moved -13.8% · over the same window, market -1.7% · sector -0.4%
- FY24Report filed Feb 5, 2025Revenue +25.0% YoY · EPS $22.63Release time unknown: Feb 4 close → Feb 6 close, the stock moved +5.5% · over the same window, market +0.8% · sector -0.6%
- FY23Report filed Jan 31, 2024Revenue +31.3% YoY · EPS $18.62Release time unknown: Jan 30 close → Feb 1 close, the stock moved +6.2% · over the same window, market -0.3% · sector +1.1%
- FY22Report filed Feb 1, 2023Revenue +25.7% YoY · EPS $24.44Release time unknown: Jan 31 close → Feb 2 close, the stock moved -4.6% · over the same window, market +2.5% · sector +0.3%
The next earnings release is estimated around Feb 3, 2027 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Novo Nordisk A/S
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 1 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Novo Nordisk A/S
Institutions we track that reported holding this stock in their most recent 13F.
- Capital World Investors0.03% of portfolio · held as of 2020 Q3 or earlier
- Baillie Gifford & Counder 0.01% of portfolio · since 2024 Q1
- Tudor Investment Corp0.01% of portfolio · since 2025 Q4
- Maverick Capital0.70% of portfolio · since 2026 Q1
- Dodge & Cox0.51% of portfolio · since 2026 Q1
- Point72 Asset ManagementNew this quarterunder 0.01% of portfolio · since 2026 Q2
- Caisse de depot (Quebec)New this quarter0.04% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Novo Nordisk A/S is classified under the Biotech & Health sector. See peers below.
Novo Nordisk A/S key financials
Based on SEC filings · as of Dec 31, 2025 · IFRS
Tap a metric name to see its meaning in the glossary.
Novo Nordisk A/S vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ETFs holding Novo Nordisk A/S
Per SEC N-PORT · 2026-06-30 · by weight · factual
NVO on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
NVO FAQ
What is Novo Nordisk A/S (NVO)?
Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Novo Nordisk A/S's key financials?
As of Dec 31, 2025 in SEC filings: Revenue growth (YoY) 6.4%, Operating margin 41.3%, Net margin 33.1%, ROE 52.8%, Debt-to-equity 0.69x. Definitions and interpretation are available on Stocklore.
Where can I analyze Novo Nordisk A/S (NVO) stock?
On Stocklore you can see NVO's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.